Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited

SBHMY

$14.54

Updated: 23/09/2026, 15:41:01

Market Cap
$12.92B
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Country
HK
Stock valuation chart
One-year closing share-price history for SBHMY
Company Profile

Sino Biopharmaceutical Limited operates as a prominent research and development-centric pharmaceutical conglomerate in the People's Republic of China, functioning as an investment holding company. Its operations are organized into three primary divisions: Modernized Chinese and Chemical Medicines, Investment activities, and other varied business ventures. The firm maintains an extensive product range covering numerous therapeutic categories. Among its offerings are oncology treatments, such as Qingkeshu tablets and Leweixin injections; cardiovascular and cerebrovascular medications, including Kaina and Anrixin tablets; hepatitis remedies like Tianqingganmei injections; and orthopedic solutions exemplified by Gaisanchun capsules. The company also produces drugs for respiratory ailments and parenteral nutritional support, for instance, Xinhaineng injections, along with a broad spectrum of other pharmaceutical preparations, such as Tuotuo tablets. Additionally, Sino Biopharmaceutical provides a selection of advanced pharmaceutical agents, including Aprepitant, Lenvatinib Mesilate, Vortioxetine Hydrobromide, and Edaravone injection. Its portfolio also features combination therapies like Amlodipine Besylate and Atorvastatin Calcium, alongside Sofosbuvir, Sitagliptin Phosphate, Colistimethate Sodium for injection, and Tofacitinib Citrate. Beyond its core pharmaceutical manufacturing, the company's diverse business interests encompass property holdings, the retail and distribution of pharmaceutical products, and providing optometry services coupled with the sale of ophthalmic goods. It manages hospitals, delivers medical management and health information consultancy, and offers biotechnology transfer and consultation services. The enterprise is also involved in the production and sale of health foods, provides orthopedic outpatient care and surgical procedures, engages in medical and health technology development, trades optical glasses, and conducts research, development, and commercialization of medical devices and active pharmaceutical ingredients. Established in 2000, the company's corporate headquarters are situated in Wan Chai, Hong Kong.

USD
OTC
CEO: S. Y. Tse
Employees: 21,435
https://www.sbpgroup.com
Asset Summaries
Latest generated summaries for SBHMY

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for SBHMY.
Share price
$14.54
Market cap
$12.92B
Exchange
OTC
Currency
USD
CEO
S. Y. Tse
Employees
21,435
IPO date
05/09/2017
Beta
0.605
Last dividend
$0.00
Day range
$12.01 – $14.54
52-week range
$11.27 – $20.16
1-day performance
0.00%
1-year performance
29.05%
Current drawdown (1Y)
-27.86%
CIK
N/A
CUSIP
82937X103
ISIN
US82937X1037
Created
07/12/2025, 14:07:27
Last update
23/09/2026, 15:41:01

Track Sino Biopharmaceutical Limited with an AI analyst

See which prediction-market events move SBHMY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to SBHMY from your Railway `news_articles` table.

No news found for this symbol.